Chronic intake of a high-cholesterol diet resulted in hepatic steatosis, focal nodular hyperplasia and fibrosis in non-obese mice

British Journal of Nutrition

Volumn 103, Issue 3, 2010, Pages 378-385

  Sumiyoshi, Maho ^a   Sakanaka, Masahiro ^a   Kimura, Yoshiyuki ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic fibrosis; Hepatic focal nodular hyperplasia; High cholesterol diet; Platelet derived growth factor

Indexed keywords

CHOLESTEROL; CHOLIC ACID; MILK FAT; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR B; CCL2 PROTEIN, MOUSE; CYTOKINE; LIPID; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR BB;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL DIET; CONTROLLED STUDY; FATTY LIVER; GALLSTONE; HYPERCHOLESTEROLEMIA; LIVER FIBROSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER LEVEL; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHOLESTEROL INTAKE; DRUG EFFECT; GLUCOSE TOLERANCE TEST; LIVER; LIVER CIRRHOSIS; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; REFERENCE VALUE;

MUS;

ANIMALS; BODY WEIGHT; CHEMOKINE CCL2; CHOLESTEROL; CHOLESTEROL, DIETARY; CYTOKINES; FATTY LIVER; GALLSTONES; GLUCOSE TOLERANCE TEST; LIPIDS; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; PLATELET-DERIVED GROWTH FACTOR; REFERENCE VALUES;

EID: 77449103003     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114509991772     Document Type: Article

References (49)

1. Reaven GM (1988) Role of insulin resistance on human disease. Diabetes 37, 1595-1607.
2. Plutzky J (2000) Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 15, 416-421.
3. Portincasa P, Moschetta A & Palasciano G (2006) Cholesterol gallstone disease. Lancet 368, 230-239.
4. Buyssens N, Kockx MM, Herman AG, et al. (1996) Centrolobular liver fibrosis in the hypercholesterolemic rabbit. Hepatology 24, 939-946.
5. Jeong WI, Jeong DH, Do SH, et al. (2005) Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci 67, 235-242.
6. Kleemann R & Kooistra T (2005) HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drug Targets Cardiovasc Haematol Disord 5, 441-453.
7. Kleemann R, Verschuren L, Erk MJ, et al. (2007) Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genomic Biol 8, R200.
8. Day CP & James OF (1998) Steatohepatitis: a tale of two 'hits'? Gastroenterology 114, 842-845.
9. Fletcher MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chem Acta 22, 393-397.
10. Zak B, Dickman RC, White EG, et al. (1954) Rapid estimation of free and total cholesterol. Am J Clin Pathol 24, 1307-1315.
11. Daniele F, Rajas F, Payrastre B, et al. (1999) Phosphatidyl-inositol 3-kinase translocates onto liver endoplasmic reticulum and may account for the inhibition of glucose-6-phosphatase during refeeding. J Biol Chem 274, 3597-3601.
12. Shapiro DJ, Imblum RL & Rodwell VW (1969) Thin-layer chromatographic assay for HMG-CoA reductase and mevalonic acid. Anal Biochem 31, 383-390.
13. Tijburg LBM, Maquedano A, Bijleveld C, et al. (1988) Effects of ethanol feeding on hepatic lipid synthesis. Arch Biochem Biophys 267, 568-579.
14. Kabir M, Rizkalla SW, Quignard-Boulangé A, et al. (1998) A high glycemic index starch diet affects lipid storage-related enzymes in normal and a lesser extent in diabetic rats. J Nutrition 128, 1878-1883.
15. Jentsch W, Derno M, Klein M, et al. (2000) Research note: is starch utilization for fat deposition in man different from that of animals? Arch Tierernahr 53, 395-398.
16. Bernardini G, Ribatti D, Morbidelli L, et al. (2002) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273, 83-101.
17. Kim MY, Byeon CW, Hong KH, et al. (2005) Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 579, 1597-1601.
18. Egashira K, Zhao Q, Kataoka C, et al. (2002) Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 90, 1167-1172.
19. Egashira K (2003) Molecular mechanisms mediating inflammation in vascular disease. Special reference to monocyte chemoattractant protein-1. Hypertension 41, 834-841.
20. Ni W, Kitamoto S, Ishibashi M, et al. (2004) Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 24, 534-539.
21. Sumiyoshi M, Sakanaka M & Kimura Y (2006) Chronic intake of high-fat and high-sucrose diets differentially affects glucose intolerance in mice. J Nutr 136, 582-587.
22. Sartipy P & Losktoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. PNAS 100, 7265-7270.
23. Weisberg SP, McCann D, Desai M, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808.
24. Kanda H, Tateya S, Tamori Y, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 1494-1505.
25. Uchiumi D, Kobayashi M, Tachikawa T, et al. (2004) Subcutaneous and continuous administration of lipopolysacchride increases serum levels of triglyceride and monocyte chemoat-tractant protein-1 in rats. J Periodontal Res 39, 120-128.
26. Kanno K, Tazuma S, Nishioka T, et al. (2005) Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 50, 942-948.
27. Kobayashi H, Tamatani T, Tamura T, et al. (2006) The role of monocyte chemoattractant protein-1 in biliary artesia. J Pediatr Surg 41, 1967-1972.
28. Gäbele E, Mühlbauer M, Dorn C, et al. (2008) Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 376, 271-276.
29. Desai MS, Mariscalco MM, Tawil A, et al. (2008) Atherogenic diet-induced hepatitis is partly dependent on murine TLR4. J Leukoc Biol 83, 1336-1344.
30. Ikejima K, Okumura K, Kon K, et al. (2007) Role of adipocy-tokines in hepatic fibrogenesis. J Gastroentrol Hepatol 22, Suppl. 1, S87-S92.
31. Watanabe S, Yaginuma R, Ikejima K, et al. (2008) Liver diseases and metabolic syndrome. J Gastroenterol 43, 509-518.
32. Bertolani C & Marra F (2008) The role of adipokines in liver fibrosis. Pathophysiology 15, 91-101.
33. Adachi M & Brenner DA (2008) High molecular weight adipo-nectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47, 677-685.
34. Isoda K, Sawada S, Ayaori M, et al. (2005) Deficiency of inter-leukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 280, 7002-7009.
35. George J, Roulot D, Koteliansky VE, et al. (1999) In vivo inhibition of rat stellate cell activation by soluble transforming growth factor b type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 96, 12719-12724.
36. Bataller R & Brenner DA (2005) Liver fibrosis. J Clin Invest 115, 209-218.
37. Gressner AM & Weiskirchen R(2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-b as major players and therapeutic targets. J Cell Mol Med 10, 76-99.
38. Yoshiji H, Kuriyama S, Noguchi R, et al. (2006) Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-b with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 17, 899-904.
39. Moreira RK (2007) Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 131, 1728-1734.
40. Leask A, Chen S, Pala S, et al. (2008) Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells. J Cell Commun Signal 2, 49-56.
41. Borkham-Kamphorst E, Hermann J, Stoll D, et al. (2004) Dominant-negative soluble PDGF-b receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 84, 766-777.
42. Borkham-Kamphorst E, van Roeyen CRC, Ostendorf T, et al. (2007) Profibrogenic potential of PDGF-D in liver fibrosis. J Heptatol 46, 1064-1074.
43. Pinzani M, Gesualdo L, Sabbah GM, et al. (1989) Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84, 1786-1793.
44. Czochra P, Klopcic B, Meyer E, et al. (2006) Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45, 419-428.
45. Vogelbruch M, Wellmann A, Maschek H, et al. (1995) Transforming growth factor b1 in human liver tumors. Verh Dtsch Ges Pathol 79, 132-136.
46. Kondo F (2001) Benign nodular hepatocellular lesions caused by abnormal hepatic circulation: etiological analysis and introduction of new concept. J Gastroenterol Hepatol 16, 1319-1328.
47. Rangheard AS, Vilgrain V, Audet P, et al. (2002) Focal nodular hyperplasia inducing hepatic vein obstruction. AJR Am J Roent-genol 179, 759-762.
48. Makhlouf HR, Abdul-Al HM & Goodman ZD (2005) Diagnosis of focal nodular hyperplasia of the liver by needle biopsy. Hum Pathol 36, 1210-1216.
49. Bioulac-Sage P, Laumonier H, Cubel G, et al. (2008) Over-expression of glutamine synthetase in focal nodular hyperplasia (part 1): early stages in the formation support the hypothesis of a focal hyper-arterialisation with venous (portal and hepatic) and biliary damage. Comp Hepatol (epublication 29 February 2008).